Molecular neuroscience

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neur

Retrieved on: 
Wednesday, November 1, 2023
Intellectual disability, Inflammasome, EAE, ASC, Mouse, NLRP3, Microglia, Neuroprotection, Phenotype, Inflammation, Research, Brain, Neurotoxicity, Neuroinflammation, Immunomodulation, M1, Molecular neuroscience, Multiple sclerosis, Spinal cord, Astrocyte, Disability, Therapy, Neuroscience, Super Meat Boy, MS, Central nervous system, Pharmaceutical industry

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • Key findings showed that NLRP3 inflammasome inhibition:
    Ameliorated pathological changes in the spinal cord and neuron damage in the brain of MS mice.
  • “It is encouraging that the research published in Molecular Neurobiology substantiates our published MS data with Inflammasome ASC Inhibitor IC 100, providing support for its use as a potential therapeutic option.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.

Switch Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Pharmaceutical, Health, Carbon, Tissue, Amgen, University of Bristol, University of East London, Migraine, University, Senior, Doctor of Philosophy, Schizophrenia, CSO, P. R. Mallory and Co Inc, Western University, Rochester, Thomas Jefferson University, Pulsus Group, Nitric oxide, Coronavirus Scientific Advisory Board, DRS, Janssen, Physiology, Research, Iron monosilicide, Johns Hopkins School of Medicine, RNA, Genentech, Princeton University, Drexel University, CNS, Conditional, Pain, Discovery, Lilly, Molecular neuroscience, Outline of health sciences, Novo Nordisk, RNA interference, Merck, Therapy, Oligonucleotide, Western University of Health Sciences, Disease, Research fellow, Pharmaceutical industry, Erenumab, Neuroscience, Chemistry, Biology

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.
  • Marc Abrams, David Bredt and James Treanor to our company’s Scientific Advisory Board,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “Together, they bring decades of experience in CNS and RNA therapies and we’re thrilled for them to join the Switch Therapeutics team.
  • Dr. Abrams spent the first 17 years of his career at Merck and Co., Inc in scientific positions of increasing responsibility.

Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer

Retrieved on: 
Wednesday, October 19, 2022
Rewind, Nerve injury, Disease, Therapy, CSO, PD, Swiss Federal Institute of Aquatic Science and Technology, Science, Multiple sclerosis, Optic neuritis, Patient, Total survey error, Research, HIV disease progression rates, University, Company, Drug discovery, Doctor of Philosophy, Industry, Remyelination, CNS, Demyelinating disease, Head, University of Zurich, California Institute for Quantitative Biosciences, Swiss Federal Institute of Technology, Molecular neuroscience, Neurodegeneration, PMV, Pharmaceutical industry

Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer.

Key Points: 
  • Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Companys Chief Scientific Officer.
  • "We warmly welcome Irene as our new CSO and are excited that she joins Rewind," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • Our goal is to progress to a clinical-stage portfolio company and we know Irene will play a significant role in advancing Rewind."
  • "Rewind Therapeutics has built a great team and comprehensive expertise in remyelination," said Irene Knuesel, Chief Scientific Officer at Rewind Therapeutics.

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Tuesday, March 29, 2022
Private Securities Litigation Reform Act, Janssen Pharmaceuticals, Biomarker, Neurodegeneration, Johns Hopkins School of Medicine, Janssen, SEC, Rockefeller University, GLOBE, University, Security (finance), Investigational New Drug, Senior, Immune system, Industry, Temple University, Hope, ALEC, Brain, U.S. Securities and Exchange Commission, Therapy, Forward-looking statement, CMO, ALS, Clinical Science (journal), Drug discovery, Molecular neuroscience, SAN, Alector, Trinity College, Patient, Merck, Innovative Medicines Initiative, Leadership, Frontotemporal dementia, Lists of diseases, Doctor of Philosophy, Clinical trial, Johnson & Johnson, Pharmaceutical industry, Vaccine, Development, Biology, Medicine, Neuroscience, Research

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer.
  • Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector.
  • We are delighted to welcome Gary to our executive leadership team, said Dr. Kenkare-Mitra.
  • Sam is pursuing a new opportunity outside of Alector though he will continue to consult with Alector.

Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

Retrieved on: 
Tuesday, August 3, 2021
Science, Biotechnology, Research, Hardware, Oncology, Health, Technology, Clinical trials, Branches of biology, Cancer, Biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Proteases, Prostate cancer, MCRPC, Advanced Accelerator Applications, Prostvac, PSMA, prostate cancer and other solid tumors, Ambrx, PSMA, PROSTATE CANCER AND OTHER SOLID TUMORS, AMBRX

The Phase 1 trial will be a multi-center, open-label, dose escalation and dose expansion study.

Key Points: 
  • The Phase 1 trial will be a multi-center, open-label, dose escalation and dose expansion study.
  • The trial will enroll up to 76 patients with advanced solid tumors whose diseases have failed prior standard therapies.
  • While non-ADC therapies are available to treat mCRPC, there is no approved therapy specifically targeting PSMA to treat prostate cancer.
  • Ambrx undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

Retrieved on: 
Wednesday, July 28, 2021
Research, Medical Supplies, FDA, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Branches of biology, Sleep disorders, Molecular neuroscience, Neuropeptides, Neuroscience, Amphetamine, Narcolepsy, G protein-coupled receptors, Orexin, Cataplexy, Hypocretin (orexin) receptor 2, Danavorexton

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.
  • Individuals with narcolepsy type 1 suffer from excessive daytime sleepiness, which might mean routinely falling asleep at work or in school.
  • This designation marks a key milestone in Takedas accelerated development efforts to bring this important potential therapy to patients with NT1.
  • A Study of TAK-994 in Participants With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2]).

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Glutamate, Biology, NMDA receptor antagonists, Molecular neuroscience, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid

An archived replay of the event will be available for one year after the conclusion of the presentation.

Key Points: 
  • An archived replay of the event will be available for one year after the conclusion of the presentation.
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer

Retrieved on: 
Thursday, June 3, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Prostate cancer, Accurin, Targeted Alpha Therapies (TAT) at Bayer, Prostate Cancer at Bayer, Xofigo® (radium Ra 223 dichloride) Injection, NUBEQA® (darolutamide)3, Bayer, Noria Therapeutics (Noria) / PSMA Therapeutics Inc., TARGETED ALPHA THERAPIES (TAT) AT BAYER, PROSTATE CANCER AT BAYER, XOFIGO® (RADIUM RA 223 DICHLORIDE) INJECTION, NUBEQA® (DAROLUTAMIDE)3, BAYER, NORIA THERAPEUTICS (NORIA) / PSMA THERAPEUTICS INC.

Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.

Key Points: 
  • Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.
  • Prostate cancer is the second most commonly diagnosed cancer in men1 and a key area of focus for Bayer.
  • About Noria Therapeutics (Noria) / PSMA Therapeutics Inc.
    Noria is a research and development company managed by experienced radiopharmaceutical development leaders and focused on the development of novel targeted alpha therapeutics and theranostic agents.
  • PSMA Therapeutics Inc. is a subsidiary of Noria to advance the platform of prostate-specific membrane antigen (PSMA) targeting radiotherapeutics.

First Patient Dosed in Japanese Prostate Cancer Imaging Study

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Biology, Prostate cancer, Declan G. Murphy, Prostate cancer screening

The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan.

Key Points: 
  • The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan.
  • The objective is to obtain safety data in a representative Japanese patient population, and to demonstrate that the targeting and biodistribution of TLX591-CDx in Japanese patients is consistent with international experience.
  • Anri Inaki MD PhD, Principal Investigator of the study, said, The development of PSMA prostate imaging in Japan has been eagerly awaited by prostate cancer patients and the urology and nuclear medicine community.
  • Dosing the first patient represents a significant first step for the Japanese domestic medicine community to deliver innovative benefits to Japanese prostate cancer patients.

NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating Narcolepsy

Retrieved on: 
Tuesday, May 18, 2021
Psychoactive drugs, Branches of biology, Molecular neuroscience, Neuroscience, Stimulants, Sleep disorders, Neuropeptides, Chloroarenes, Orexin, Mazindol, Reuptake inhibitor, Narcolepsy

Narcolepsy is caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.

Key Points: 
  • Narcolepsy is caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.
  • NLS believes that the new data also support prior in-vitro data from studies conducted by the Company demonstrating the partial binding affinity of mazindol to OX2R, which NLS believes is a key pathway that mediates mazindol\'s stimulant-like effects.
  • We believe that Quiliencewill provide a differentiated solution in this treatment category given mazindol\'s dual mechanism of action, namely orexin pathway activation and pan-monoaminergic reuptake inhibition in the brain.
  • NLS completed a Phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD.